tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Zealand Pharma initiated with an Overweight at Barclays

Barclays analyst Yihan Li initiated coverage of Zealand Pharma (ZLDPF) with an Overweight rating and DKK 560 price target The firm says the company’s story is intact with long-term upside despite recent competitor pressure and potential amylin setbacks. Current share levels offer an attractive entry point, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1